Faeth Therapeutics reported positive preliminary Phase 2 clinical results evaluating its investigational small molecule PIKTOR in advanced endometrioid endometrial cancer. In the ongoing PIK-201 trial, the combination of PIKTOR and paclitaxel demonstrated a confirmed objective response rate of 33% across 36 evaluable patients. Faeth Chief Executive Anand Parikh stated: "Targeting multiple components of the PI3K and mTOR pathways could provide a vital treatment approach for advanced endometrial cancer."
The study achieved a disease control rate of 83% and a preliminary median progression-free survival of 7.4 months among heavily pretreated individuals. PIKTOR is engineered as an oral targeted agent designed to overcome chemotherapy resistance by selectively suppressing cancer cell metabolic signaling. Clinical investigators reported manageable safety profiles without unexpected dose-limiting toxicities during the multi-center evaluation.
Based on the preliminary findings, corporate management plans to initiate consultations with regulatory authorities regarding Phase 3 registration trial design. Endometrial carcinomas represent a substantial unmet medical need, where secondary treatment options historically yield limited durable response rates. Company researchers are simultaneously exploring therapeutic potential for the compound in clinical models of refractory solid tumors.
Faeth confirmed preparations to present comprehensive multi-center clinical datasets at upcoming international oncology congresses.
